• Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

  • 2024/10/17
  • 再生時間： 43 分
  • ポッドキャスト

Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • “Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company’s recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.

    See omnystudio.com/listener for privacy information.
    続きを読む 一部表示

あらすじ・解説

“Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company’s recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.

See omnystudio.com/listener for privacy information.
個人ファイナンス 経済学 衛生・健康的な生活
続きを読む 一部表示

Guardant Health's Tests Are Pioneering a Shift in Precision Oncologyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。